CGON

CG Oncology, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001991792

$59.56 +3.33% $5.3B

20 New Institutional Positions7 Institutional Exits

Vol

Market Cap$5.3B

Cap SizeMid Cap

Analyst ConsensusStrong Buy (91%)

Inst. Holders50 funds

Inst. Value$3.1B

Inst. Activity20 buys / 7 sells

Insider Activity0B / 3S

Insider Net $-$1.2M

Reddit Sentiment50° Neutral

SEC Reports8

Press Releases2

Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001991792·Prev Close $57.64

Recent Activity

Jun 12, 2026 SEC

A significant institutional cluster formed in CG Oncology during Q3 2024, with 14 buyers accumulating $41.7M in net new

INST-CLUSTER — Impact 6/10

Jun 9, 2026 short_volume

Short Volume: CGON — 64.6% short (0.4M / 0.6M)

Short: 417,438 | Exempt: 130 | TRF Vol: 646,558 | Short Ratio: 64.6% | Off-exchange volume (dark poo

Jun 4, 2026 Insider

Liu Brian Guan-Chyun was granted 9,354 shares

Director

Jun 4, 2026 Insider

POST LEONARD E acquired via exercise 1,000 shares

Director @ $0.6000 ($600.00)

Jun 4, 2026 Insider

POST LEONARD E sold 1,000 shares

Director @ $54.50 ($54.5K)

May 26, 2026 SEC

CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur

8-K — Impact 3/10

May 8, 2026 SEC

CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and tot

8-K — Impact 5/10

Inst.

RTW INVESTMENTS, LP — DOUBLED

6,984,808 shares ($472.7M)

Price Targets

$90.29 +51.6% upside Strong Buy

Current $59.56 Low $80.00 Median $88.50 High $108.00 14 analysts

$80.00 $108.00

Analyst Ratings

Strong Buy91% buy · 22 analysts

5Strong Buy

15Buy

2Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
May 19, 2026	Wolfe Research	INITIATE	Peer Perform
May 18, 2026	HC Wainwright & Co.	REITERATE	Buy → Buy
May 14, 2026	Truist Securities	REITERATE	Buy → Buy
May 11, 2026	JP Morgan	MAINTAIN	Overweight → Overweight
May 11, 2026	RBC Capital	MAINTAIN	Outperform → Outperform

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.64 ▼ -10.3%	$-0.73 — $-0.52	-19% YoY	12
Next Q	$-0.67 ▼ -6.9%	$-0.77 — $-0.53	-17% YoY	12
Current FY	$-2.66 ▼ -11.0%	$-3.11 — $-1.23	-28% YoY	13
Next FY	$-2.78 ▼ -41.1%	$-3.68 — $-1.32	-5% YoY	12

Latest Reports

BULLISH INST-CLUSTER 6/10

A significant institutional cluster formed in CG Oncology during Q3 2024, with 14 buyers accumulating $41.7M in net new

Jun 12, 2026

NEUTRAL 8-K 3/10

CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur

May 26, 2026

BULLISH Press 6/10

CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at

May 15, 2026

Top Institutional Holders

Fund	Value	Move
NOMURA ASSET MANAGEMENT CO	—	—
RTW INVESTMENTS, LP	$472.7M	DOUBLED
WELLINGTON MANAGEMENT GROUP LLP	$363.5M	DOUBLED
BlackRock, Inc.	$342.7M	—
FMR LLC	$254.8M	—

Recent Insider Trades

Date	Insider	Type	Value
Jun 4, 2026	Liu Brian	A	$0.00
Jun 4, 2026	POST LEONARD	M	$600.00
Jun 4, 2026	POST LEONARD	SELL	$54.5K
Jun 4, 2026	POST LEONARD	A	$0.00
Jun 4, 2026	Mulay James	A	$0.00

Reddit Sentiment

50°

Neutral

Bearish Neutral Bullish

2 mentions 0 bullish 0 bearish

50 institutional holders with $3.1B total value (46,150,934 shares) as of 2026-Q1. Top holders: NOMURA, RTW, WELLINGTON. Net buying activity: 20 institutions added/increased vs 7 reduced.

Top Institutional Holders — 2026-Q1

#	Fund	Shares	Value	% of Tracked	Last Move
1	NOMURA ASSET MANAGEMENT CO LTD	—	$0.00	0.0%	—
2	RTW INVESTMENTS, LP	6,984,808	$472.7M	15.3%	DOUBLED +247.1%
3	WELLINGTON MANAGEMENT GROUP LLP	5,371,232	$363.5M	11.8%	DOUBLED +190.3%
4	BlackRock, Inc.	5,064,180	$342.7M	11.1%	—
5	FMR LLC	3,764,844	$254.8M	8.2%	—
6	VANGUARD PORTFOLIO MANAGEMENT LLC	3,095,098	$209.5M	6.8%	—
7	VANGUARD CAPITAL MANAGEMENT LLC	3,033,625	$205.3M	6.6%	—
8	STATE STREET CORP	2,647,054	$179.2M	5.8%	ADD +46.4%
9	FRANKLIN RESOURCES INC	1,507,005	$102.0M	3.3%	—
10	BANK OF AMERICA CORP /DE/	1,449,364	$98.1M	3.2%	ADD +59.0%
11	GOLDMAN SACHS GROUP INC	1,159,239	$78.5M	2.5%	—
12	DRIEHAUS CAPITAL MANAGEMENT LLC	999,623	$67.7M	2.2%	NEW
13	ALLIANCEBERNSTEIN L.P.	1,290,087	$53.6M	1.7%	—
14	Clearbridge Investments, LLC	730,283	$49.4M	1.6%	—
15	Polar Capital Holdings Plc	704,461	$47.7M	1.5%	TRIM -35.9%
16	FARALLON CAPITAL MANAGEMENT LLC	674,000	$45.6M	1.5%	DOUBLED +8325.0%
17	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	542,378	$36.7M	1.2%	—
18	MORGAN STANLEY	520,213	$35.2M	1.1%	—
19	Woodline Partners LP	492,891	$33.4M	1.1%	—
20	JENNISON ASSOCIATES LLC	476,136	$32.2M	1.0%	ADD +68.5%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
RTW INVESTMENTS, LP	DOUBLED	2,012,127	6,984,808	+247.1%	$472.7M	2026-Q1
DRIEHAUS CAPITAL MANAGEMENT LLC	NEW	—	999,623	—	$67.7M	2026-Q1
Polar Capital Holdings Plc	TRIM	1,098,662	704,461	-35.9%	$47.7M	2026-Q1
FARALLON CAPITAL MANAGEMENT LLC	DOUBLED	8,000	674,000	+8325.0%	$45.6M	2026-Q1
JENNISON ASSOCIATES LLC	ADD	282,506	476,136	+68.5%	$32.2M	2026-Q1
ADAGE CAPITAL PARTNERS GP, L.L.C.	NEW	—	399,858	—	$27.1M	2026-Q1
Point72 Asset Management, L.P.	DOUBLED	151,363	399,392	+163.9%	$27.0M	2026-Q1
Pictet Asset Management Holding SA	TRIM	1,349,527	398,005	-70.5%	$26.9M	2026-Q1
FIRST TRUST ADVISORS LP	ADD	181,798	333,192	+83.3%	$22.6M	2026-Q1
AMERIPRISE FINANCIAL INC	ADD	240,477	311,523	+29.5%	$21.1M	2026-Q1
TD ASSET MANAGEMENT INC	ADD	186,448	288,756	+54.9%	$19.5M	2026-Q1
HSBC HOLDINGS PLC	NEW	—	187,765	—	$12.7M	2026-Q1
FEDERATED HERMES, INC.	DOUBLED	3,500	148,750	+4150.0%	$10.1M	2026-Q1
SCHRODER INVESTMENT MANAGEMENT GROUP	TRIM	281,059	156,327	-44.4%	$10.0M	2026-Q1
Universal- Beteiligungs- und Servicegesellschaft mbH	DOUBLED	37,834	144,103	+280.9%	$9.8M	2026-Q1
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	TRIM	201,918	136,841	-32.2%	$9.3M	2026-Q1
Invesco Ltd.	DOUBLED	38,140	91,994	+141.2%	$6.2M	2026-Q1
Rafferty Asset Management, LLC	TRIM	106,052	67,979	-35.9%	$4.6M	2026-Q1
PICTON MAHONEY ASSET MANAGEMENT	DOUBLED	2,850	67,404	+2265.1%	$4.6M	2026-Q1
VOYA INVESTMENT MANAGEMENT LLC	ADD	43,721	57,291	+31.0%	$3.9M	2026-Q1
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	TRIM	55,151	21,776	-60.5%	$1.5M	2026-Q1
SEI INVESTMENTS CO	DOUBLED	8,547	18,089	+111.6%	$1.2M	2026-Q1
Allianz Asset Management GmbH	ADD	7,600	12,300	+61.8%	$832.5K	2026-Q1
NISA INVESTMENT ADVISORS, LLC	ADD	729	1,288	+76.7%	$87.2K	2026-Q1
Rockefeller Capital Management L.P.	DOUBLED	192	964	+402.1%	$65.2K	2026-Q1

11 unique insiders with 20 transactions. Net insider value: -$1.2M ($0.00 bought, $1.2M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Jun 4, 2026	Liu Brian Guan-Chyun	Director	AWARD	9,354	—	—
Jun 4, 2026	POST LEONARD E	Director	EXERCISE	1,000	$0.6000	$600.00
Jun 4, 2026	POST LEONARD E	Director	SELL	1,000	$54.50	$54.5K
Jun 4, 2026	POST LEONARD E	Director	AWARD	9,354	—	—
Jun 4, 2026	Mulay James	Director	AWARD	9,354	—	—
Jun 4, 2026	Graf Susan E	Director	AWARD	9,354	—	—
Jun 4, 2026	Rossi Christina	Director	AWARD	9,354	—	—
Jun 4, 2026	Tong Victor Edward Jr	Director	AWARD	9,354	—	—
Apr 17, 2026	Mulay James	Director	EXERCISE	15,600	$36.63	$571.4K
Apr 17, 2026	Mulay James	Director	SELL	15,600	$73.01	$1.1M
Apr 15, 2026	Kuan Arthur	Chief Executive Officer	AWARD	271,600	—	—
Apr 15, 2026	DETORE JAMES M.	Chief Financial Officer	AWARD	90,574	—	—
Apr 15, 2026	Kasturi Vijay	Chief Medical Officer	AWARD	79,216	—	—
Apr 15, 2026	Patterson Joshua F.	See Remarks	AWARD	45,266	—	—
Apr 15, 2026	Bellete Ambaw	President and COO	AWARD	107,508	—	—
Mar 16, 2026	Mulay James	Director	SELL	654	$63.50	$41.5K
Mar 16, 2026	Mulay James	Director	EXERCISE	654	$3.72	$2.4K
Mar 12, 2026	Kuan Arthur	Chief Executive Officer	TAX W/H	1,847	$60.15	$111.1K
Mar 12, 2026	Kuan Arthur	Chief Executive Officer	EXERCISE	64,612	$1.72	$111.1K
Mar 4, 2026	Kuan Arthur	Chief Executive Officer	EXERCISE	102,871	$1.72	$176.9K

8 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 4.3/10.

BULLISH INST-CLUSTER 6/10

A significant institutional cluster formed in CG Oncology during Q3 2024, with 14 buyers accumulatin

Jun 12, 2026

NEUTRAL 8-K 3/10

CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and a

May 26, 2026

MIXED 8-K 5/10

CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's

May 8, 2026

NEUTRAL PRESS-RELEASE 5/10

CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.

May 8, 2026

NEUTRAL DEFA14A 3/10

CG Oncology filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. This

Apr 24, 2026

NEUTRAL 144 3/10

James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares

Apr 17, 2026

NEUTRAL 8-K 3/10

CG Oncology appointed Jim DeTore as Chief Financial Officer, effective April 13, 2026. The appointme

Apr 13, 2026

BULLISH INST-CLUSTER 6/10

Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th

Feb 28, 2026

BULLISH 6/10

CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, sho

May 15, 2026

NEUTRAL 5/10

CG Oncology reported financial results for Q4 and full year 2025, highlighting a cash position of $7

Feb 28, 2026

Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 5 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$90.29 mean target +51.6% upside Strong Buy (3.00)

$80.00 Low $108.00 High

Metric	Value
Current Price	$59.56
Target Low	$80.00
Target Mean	$90.29
Target Median	$88.50
Target High	$108.00
# Analysts	14
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.64	$-0.73	$-0.52	-18.8%	-10.3%	3↑ 6↓	$0.0B	0.0%	12
Next Q 2026-09-30	$-0.67	$-0.77	$-0.53	-17.1%	-6.9%	3↑ 6↓	$0.0B	-22.6%	12
Current FY 2026-12-31	$-2.66	$-3.11	$-1.23	-27.7%	-11.0%	2↑ 8↓	$0.0B	190.4%	13
Next FY 2027-12-31	$-2.78	$-3.68	$-1.32	-4.7%	-41.1%	0↑ 10↓	$0.1B	670.5%	12

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.642
7d ago	$-0.647	+0.005
30d ago	$-0.582	-0.060
60d ago	$-0.589	-0.052
90d ago	$-0.678	+0.037

7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 19, 2026	Wolfe Research	INITIATE	—	Peer Perform
May 18, 2026	HC Wainwright & Co.	REITERATE	Buy	Buy
May 14, 2026	Truist Securities	REITERATE	Buy	Buy
May 11, 2026	JP Morgan	MAINTAIN	Overweight	Overweight
May 11, 2026	RBC Capital	MAINTAIN	Outperform	Outperform
May 11, 2026	Truist Securities	REITERATE	Buy	Buy
May 11, 2026	Wedbush	MAINTAIN	Outperform	Outperform
Apr 27, 2026	RBC Capital	MAINTAIN	Outperform	Outperform
Apr 17, 2026	JP Morgan	MAINTAIN	Overweight	Overweight
Apr 7, 2026	HC Wainwright & Co.	MAINTAIN	Buy	Buy
Feb 27, 2026	HC Wainwright & Co.	MAINTAIN	Buy	Buy
Feb 10, 2026	Truist Securities	MAINTAIN	Buy	Buy
Jan 21, 2026	RBC Capital	MAINTAIN	Outperform	Outperform
Jan 16, 2026	Piper Sandler	MAINTAIN	Overweight	Overweight
Jan 12, 2026	Truist Securities	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	5	15	2	91%
May 1, 2026	5	15	1	95%
Apr 1, 2026	5	15	1	95%
Mar 1, 2026	5	15	1	95%
Feb 1, 2026	5	15	1	95%
Jan 1, 2026	5	15	1	95%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

50°

Neutral

Bearish Neutral Bullish

2 mentions 0 bullish 0 bearish 2 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Bearish	Threads
Jun 13, 2026	1	50° Neutral	0	0	1
Jun 13, 2026	1	50° Neutral	0	0	1

Recent Reddit Threads

r/wallstreetbets Neutral 2d 2h ago

Bladder cancer short squeeze

▲ 1 💬 2 ⚡ 0.5

Jun 9, 2026

short_volume

Short Volume: CGON — 64.6% short (0.4M / 0.6M)

Short: 417,438 | Exempt: 130 | TRF Vol: 646,558 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)

Jun 2, 2026

short_volume

Short Volume: CGON — 56.1% short (0.3M / 0.5M)

Short: 293,444 | Exempt: 152 | TRF Vol: 523,435 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)

May 28, 2026

other

CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President &

May 15, 2026

fda

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Ev

May 11, 2026

earnings

CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed a

May 11, 2026

earnings_calendar

CGON Q1 2026 Earnings Scheduled — 2026-05-11

May 8, 2026

earnings

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter

May 7, 2026

earnings_calendar

CGON Q1 2026 Earnings Scheduled — 2026-05-07

Apr 8, 2026

short_volume

Short Volume: CGON — 60.6% short (0.3M / 0.6M)

Short: 343,225 | Exempt: 0 | TRF Vol: 566,655 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)

Apr 2, 2026

Clinical Trial

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase Phase 3 — ACTIVE_NOT_RECRUITING

Apr 2, 2026

clinical_trial_readout

T-60d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)

Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Sponsor: CG Oncology, Inc. Phase: P

Apr 1, 2026

clinical_trial_readout

T-90d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)

Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Sponsor: CG Oncology, Inc. Phase: P

Mar 30, 2026

clinical_trial_readout

T-90d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)

Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Sponsor: CG Oncology, Inc. Phase: P

Mar 30, 2026

clinical_trial_readout

T-90d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)

Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Sponsor: CG Oncology, Inc. Phase: P

Mar 26, 2026

short_interest

FTD: CGON — 9,432 shares ($0.6M) failed to deliver

Settlement: 20260326, Price: $65.81, FTD Value: $620,719.92, CG ONCOLOGY INC COM

Mar 23, 2026

short_volume

Short Volume: CGON — 57.1% short (0.5M / 0.8M)

Short: 480,624 | Exempt: 17,373 | TRF Vol: 842,429 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)